Douliu City

Nocturia, a common and troubling condition among older adults in Taiwan, often disrupts sleep quality and affects mental health while increasing the risk of falls. This research evaluates a new community-based approach that combines digital health technology and behavioral therapy to manage nocturia in people aged 55 and older who experience two or more nighttime voids. The goal is to reduce nocturnal voiding frequency, improve quality of life, and explore reducing medication reliance. Participants are divided into two groups. The intervention group uses a non-contact home uroflowmetry device and a voiding diary to track urinary patterns, receiving real-time feedback. They also get personalized lifestyle advice such as fluid restriction and leg elevation, alongside psychiatric screening for sleep and mood disorders. The control group receives general health education and follow-up without these devices or personalized interventions. Throughout the study, participants record their voiding habits for 2-3 consecutive days monthly over six months. Researchers assess nocturnal void frequency, sleep quality, mental health, anxiety, quality of life, and fall or emergency events at the start, three months, and six months after randomization. This comprehensive monitoring helps evaluate the effectiveness of the community-based management model integrating digital tools and behavioral support.

Researchers are evaluating AZD8965 in a Phase IIb trial to study its safety, tolerability, and effectiveness in treating Idiopathic Pulmonary Fibrosis IPF. The study compares three doses of AZD8965 to a placebo in participants with IPF, including those who are on stable doses of approved antifibrotic therapies such as nintedanib, pirfenidone, or nerandomilast, as well as those not taking antifibrotic treatment. The trial is randomized, placebo-controlled, double-blind, and parallel-group in design. Participants are assigned to one of four groups placebo, low dose AZD8965, medium dose AZD8965, or high dose AZD8965. The treatment lasts for 24 weeks, during which participants receive their assigned medication. The study includes approximately 360 participants across around 200 sites worldwide. Researchers aim to assess the clinical efficacy of AZD8965 by measuring changes in lung function and study the relationship between dose and outcomes. During the study, participants will undergo various assessments including lung function tests such as forced vital capacity FVC, monitoring for adverse events, and pharmacokinetic analyses of AZD8965. Safety and tolerability are monitored up to 25 weeks. Researchers will also track any serious adverse events and treatment discontinuations. The total participation time covers the 24-week treatment period with scheduled visits to assess the study outcomes and participant health.

This research aims to explore the Microbiota-gut-brain axis, a communication system between the gut and brain, particularly in relation to Parkinsons disease PD. The study investigates how gut bacteria and intestinal function may affect PD development by examining the relationship between intestinal FDG activity patterns and dopamine transporter changes using imaging techniques. The study focuses on understanding the role of gut microbiota and intestinal permeability in PD pathogenesis and brain function. Participants undergo imaging tests including 18F-FDG PET to evaluate gut microbiota composition and Tc-99m TRODAT-1 SPECT to assess the dopamine system in the brain. The study includes PD patients and a control group without PD, and the research team will analyze correlations between bowel FDG uptake and dopamine transporter degeneration. Both imaging procedures are part of the study assessments covered by research funds. During the study, participants will be evaluated using visual scoring of physiological parameters related to bowel FDG uptake over an average period of two years. Clinical staging of PD will be assessed using specific rating scales. Participants must fast before imaging and avoid certain medications. The study will monitor imaging results and clinical data to better understand PDs underlying mechanisms and explore potential new therapeutic approaches.

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with Chronic Obstructive Pulmonary Disease COPD who have a higher risk for heart and lung events. This Phase III study is randomized, double-blind, and conducted at multiple centers, focusing on participants with COPD and elevated cardiopulmonary risk. Participants will receive either the triple therapy inhaler or the dual therapy inhaler, both administered twice daily. The study compares these two inhalers over a period of up to three years, monitoring for serious cardiac or COPD events. The trial includes careful evaluation of various heart and lung-related health events during this period. During the study, participants will be closely monitored through regular visits, assessments, and tests to measure lung function, heart events, and COPD exacerbations. Researchers will track the time until the first severe cardiac or COPD event and evaluate other cardiovascular and respiratory outcomes over up to three years. Participants will also be assessed for their ability to properly use the inhaler and adherence to the study protocol throughout the trial.

Researchers are evaluating if adding LY3537982 olomorasib to standard anti-cancer drugs improves treatment for participants with untreated advanced non-small cell lung cancer NSCLC that has a specific KRAS G12C gene change. This Phase 3 treatment study includes participants with locally advanced or metastatic NSCLC and aims to compare this combination against standard care. The study is sponsored by Eli Lilly and Company and could last up to 3 years depending on individual response and disease progression. Participants receive LY3537982 orally combined with pembrolizumab given intravenously in 21-day cycles. Some groups also receive chemotherapy drugs pemetrexed and platinum cisplatin or carboplatin intravenously. There are different dose levels and combinations being tested, including placebo groups for comparison. Treatment continues until specific discontinuation criteria are met. Parts of the study are randomized and double-blinded, with some parts non-randomized for safety lead-in. During the study, participants have regular assessments including imaging scans to measure tumor response, blood tests, and questionnaires about symptoms and quality of life. Researchers monitor side effects and survival outcomes. The main measures include progression-free survival and treatment-emergent adverse events over about one year, with overall survival followed for up to three years. Participants are closely followed throughout treatment and after to evaluate the effects and safety of the study medications.

Researchers are evaluating the safety, tolerability, and effectiveness of baxdrostat compared to a placebo in adults aged 18 years and older with Primary Aldosteronism PA. This Phase III, global study involves approximately 250 participants and aims to reduce seated blood pressure and normalize the Renin Angiotensin Aldosterone System RAAS. Participants may have prior treatment with Mineralocorticoid Receptor Antagonists MRAs or potassium-sparing diuretics. Participants will be randomly assigned to receive either baxdrostat or a matching placebo, both given orally once daily. The dose may be increased after two weeks depending on the participants clinical response and how well they tolerate the medication. The study is conducted across about 90 centers in 12 countries and involves parallel groups. Throughout the study, participants will have their seated systolic blood pressure and RAAS activity measured at week 8 to assess changes from baseline. Additional assessments include monitoring potassium levels, urine aldosterone, and albumin levels up to week 52. Safety and treatment effects will be regularly evaluated during visits. Total participation spans from screening through treatment and follow-up visits as scheduled.

Researchers are evaluating a new approach to Pap smear screening to improve cervical cancer screening participation among women aged 25 and above. This multicenter randomized controlled trial applies the peak-end concept by adding a non-painful step at the end of the Pap test. The study is the first to examine whether this modified Pap test can increase participation rates in cervical cancer screening and reduce recalled pain related to the procedure. Participants are randomly assigned to receive either the traditional Pap test or a modified version where, after sample collection, the speculum remains fixed in place for 15 seconds before removal. This additional step is designed to be non-painful and is performed behind a privacy curtain. All operators follow standardized procedures, and the study includes blinding of participants and cytopathologists to group assignments. The trial plans to recruit at least 248 women across multiple centers in the NTUH Healthcare System, with half receiving the modified test. During the study, participants provide written informed consent and undergo interviews to collect health, lifestyle, and psychological information. Measurements include anxiety scores, pain ratings at various time points, and medical history. Researchers will analyze cervical cancer screening participation at 1 and 3 years, along with real-time and recalled pain scores. The study includes careful monitoring and statistical analyses to assess the effect of the intervention on screening uptake and pain perception over time.

Researchers are studying somatic symptom disorder SSD, a psychiatric condition characterized by distressing physical symptoms and related psychological issues. This study aims to develop and test an integrative psychotherapy combining cognitive-behavioral therapy CBT and biofeedback therapy to assess its effects on treating SSD. The research uses a randomized controlled design with a waiting list control group to compare outcomes like patient health and health anxiety. Participants in the experimental group will receive eight sessions of CBT and biofeedback therapy over three months. The control group will initially be on a waiting list without intervention, with data collected during this observation period. Afterward, they will also receive the same psychotherapy as the experimental group. Biofeedback therapy involves monitoring biological signals related to stress and relaxation to help patients understand their connection to physical and mental responses. Throughout the study, participants will be assessed using questionnaires such as the Patient Health Questionnaire-15 and Health Anxiety Questionnaire, along with other psychological and biological measures like depression, anxiety, cognition about health, heart rate variability, and skin conductance. The primary outcomes will be measured at week 12 compared to baseline. The study is sponsored by National Taiwan University Hospital and includes adults aged 20 to 70 years with confirmed SSD.

Researchers are evaluating the effectiveness of two simulation training methods, In-situ Simulation ISS and Off-site Simulation OSS, using the A-C-L-S teamwork model to improve adult non-trauma cardiac arrest resuscitation teams. This study uses a two-group non-randomized pre-post design conducted at two different campuses of the National Taiwan University Hospital Yunlin Branch. The goal is to compare team performance and patient outcomes between teams trained in real clinical environments versus those trained in dedicated simulation centers. Participants in the ISS group receive high-fidelity simulation training in their actual emergency department, including a 20-minute briefing, 10-minute simulation exercise, and 30-minute debriefing focused on teamwork and non-technical skills. The OSS group undergoes similar training at a separate simulation center with the same timing and teamwork focus but outside the clinical setting. Both groups follow the A-C-L-S model for structuring team roles during adult non-trauma resuscitation. Throughout the one-year study period, team performances are assessed by blinded external experts using video recordings and the Team Emergency Assessment Measure TEAM scale to evaluate non-technical skills. Secondary outcomes include timing of resuscitation steps, quality of chest compressions, and patient return of spontaneous circulation rates. Data collection aims to support evidence-based education, improve resuscitation efficiency, and enhance institutional teaching and research capabilities.

This research aims to compare pain control methods for patients with hip fractures in the emergency department. It evaluates ultrasound-guided femoral nerve blocks performed by emergency physicians against the usual use of pain medications like opioids or NSAIDs. The study focuses on how quickly pain relief is achieved, the amount of rescue pain medication needed, and patient satisfaction, while monitoring for adverse effects and complications. Participants receive either an ultrasound-guided femoral nerve block, where local anesthetic is injected around the femoral nerve using ultrasound, or traditional intravenous or intramuscular pain medications. The study uses a prospective before-and-after design, enrolling patients aged 20 and older who stay in the emergency department for at least two hours. Pain severity is assessed using a 0-10 numerical rating scale at 30-minute intervals. During the study, researchers measure pain relief within two hours after treatment, patient satisfaction, adverse effects, and complications related to nerve blocks up to one week after the procedure or hospital discharge. Pain scores are recorded every 30 minutes before and after pain management. The total participation time includes at least two hours in the emergency department with follow-up for complications after discharge.